Advertisement

Interferone pp 269-287 | Cite as

Die topische Behandlung solider Tumoren mit Interferonen

  • B. J. Schmitz-Dräger
  • R. Ackermann

Zusammenfassung

Die natürliche Rolle der Interferone (IFN) im Organismus und ihre spezifische Bedeutung im Rahmen der antitumoralen Immunreaktionen konnte bislang nicht eindeutig definiert werden. In vitro und in verschiedenen Tierexperimenten konnten ebenso direkte zytotoxische als auch immunmodulierende Effekte nachgewiesen werden. Interferone stimulieren in vitro und in vivo verschiedene Zellen des Immunsystems. Abhängig vom verwendeten Typ kommt es zu einer unterschiedlich ausgeprägten Stimulation von Monozyten, Makrophagen, Killer-Zellen, natürlichen Killer-Zellen, T-Lymphozyten und B-Lymphozyten. Die Aktivierung der verschiedenen Kompartimente des Immunsystems kann zwar bestimmt werden, da aber die Bedeutung dieser Zellen für die antitumorale Reaktion im Menschen nicht bekannt ist, bleibt die Relevanz der Beobachtungen für den Therapieerfolg unklar. Bei soliden Tumoren stellt sich darüber hinaus das Problem, daß die üblicherweise im peripheren Blut nachgewiesenen Reaktionen für die lokale Situation nicht repräsentativ sind [61, 63].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Ackermann D, Biedermann C, Bailly G, Studer U (1986) Behandlung oberflächlicher Blasentumoren mit rIFN-aA-Instillation (Roferon A): eine Phase I und II Studie. In: Ackermann R (Hrsg) Verhandlungsbericht der Deutschen Gesellschaft für Urologie, Springer, Berlin, p 211–212Google Scholar
  2. 2.
    Berek JS, Hacker NF, Lichtenstein A, Jung T, Spina C, Knox RM, Brady J, Greene T, Ettinger LM, Lagasse LD, Bonnern EM, Spiegel RJ, Zighelboim J (1985) Intraperitoneal recombinant a-interferon for „salvage“ immunotherapy in stage III epithelial ovarian cancer: a gynecologic oncology group study. Cancer Res 45: 4447–4453PubMedGoogle Scholar
  3. 3.
    Borden EC, Yamamoto N, Hogan TF, Edwards BS, Bryan GT (1981) In: Münk K, Kirchner H (Hrsg) Interferon. Properties, mode of action, production, clinical applica-tion. S. Karger, Basel, pp 42–52Google Scholar
  4. 4.
    Borden EC, Edwards BS, Hawkins MJ, Merritt JA, Sielaff KM, Groveman DS, Za- remba KS, Schiller J, Willson JVK (1985) Design considerations for phase II trials of interferons in bladder, breast, and colorectal carcinomas. In: Zoon K (Hrsg) Interferon: Research, clinical application, and regulatory consideration. Elsevier, North Holland, pp 207–217Google Scholar
  5. 5.
    Brouty-Boye D, Mogensen KE, Gresser I (1985) Effects of long-term treatment of human carcinoma cells with interferon a. Eur J Cancer Clin Oncol 21: 507–514PubMedCrossRefGoogle Scholar
  6. 6.
    Coleman DV (1985) Evaluation of interferon treatment of cervical intraepithelial neoplasia. Acta cytol 29: 192–193PubMedGoogle Scholar
  7. 7.
    Coleman DV, Wickenden C, Malcolm DB (1986) Association of human papillomavirus with squamous carcinoma of the uterine cervix. Ciba Found Sympo 120: 175–189Google Scholar
  8. 8.
    Damle NK, Gupta S (1981) Autologous mixed lymphocyte reaction in man. II. Histamine-induced suppression of the autologous mixed lymphocyte reaction by T-cell subsets defined with monoclonal antibodies. J Clin Immunol 1: 241–249Google Scholar
  9. 9.
    De Palo G, Stefanon B, Rilke F, Pilotti S, Ghione M (1985) Human fibroblast interferon in cervical and vulvar intraepithelial neoplasia associated with viral cytopathic effects: a pilotstudy. J Repro Med 30: 404–408Google Scholar
  10. 10.
    Duff TA, Borden E, Bay J, Piepmeier J, Sielaff K (1986) Phase II trial of interferon-ß for treatment of recurrent glioblastoma multiforme. J Neurosurg 64: 408–413PubMedCrossRefGoogle Scholar
  11. 11.
    Durie BGM, Young LA, Salmon SE (1983) Human myeloma in vitro colony growth: Interrelationships between drug sensitivity, cell kinetics, and patient survival duration. Blood 61: 929–934Google Scholar
  12. 12.
    Ebert T, Schmitz-Dräger BJ, Ackermann R (1986) Untersuchungen zum Einfluß der harnpflichtigen Substanzen auf intravesikal appliziertes alpha-Interferon. 8. Symp Exp Urol, MainzGoogle Scholar
  13. 13.
    Flodgren P, Borgström S, Jönsson PE, Lindström C, Sjögren HO (1983) Metastatic malignant melanoma: regression induced by combined treatment with interferon ( HuIFN- a(Le)) and Cimetidine. Int J Cancer 32: 657–665Google Scholar
  14. 14.
    Greenway HT, Cornell RC, Tanner DJ, Peets E, Bordin GM, Nagi C (1986) Treatment of basal cell carcinoma with intralesional interferon. J Acad Dermatol 15: 437–443CrossRefGoogle Scholar
  15. 15.
    Gresser I (1983) The antitumor effects of interferon in mice. In: SDikora K (Hrsg) Interferon and cancer. Plenum, New York, pp 65–76Google Scholar
  16. 16.
    Grups JW, Frohmüller HGW (1988) Antiproliferative effects of interferon against human bladder carcinoma cell lines in vitro. Urol int 43: 265–268PubMedCrossRefGoogle Scholar
  17. 17.
    Haase KD, Lange OF (1988) Lokale Interferontherapie metastatisch bedingter Osteolysen. TumorDiag Ther 9: 96–99Google Scholar
  18. 18.
    Hill NO (1983) Interferon alpha and Cimetidine combination in malignant melanoma. In: Kishida T (Hrsg) Interferons. Kyoto, pp 227–238Google Scholar
  19. 19.
    Hoeltl W, Hasun R, Albrecht W, Marberger M (1987) Topical alfa-2b-Interferon low dose vs. high dose vs. Etoglucide for preventing recurrent superficial bladder cancer. 8. Eur Conf Clin Oncol, MadridGoogle Scholar
  20. 20.
    Hoffmeister H (1987) Bevölkerungsbezogene Krebsregister in der Bundesrepublik Deutschland. MMV Medizin, MünchenGoogle Scholar
  21. 21.
    Horoszewicz JS, Leong SS, Ito M, Buffett RF, Karakousis C, Holyoke E, Job L, Dolen JG, Carter WA (1978) Human fibroblast interferon in human neoplasia: clinical and laboratory study. Cancer Treat Rep 62: 1899–1906PubMedGoogle Scholar
  22. 22.
    Ikeda S, Takaharshi M, Kato T (1985) Phase II study of recombinant human interferon a A in skin malignant tumors. Proc 16th Int Congress on Chemother 1: 212Google Scholar
  23. 23.
    Ikic D, Nola P, Maricic Z, Smudj K, Oresic V, Knezevic M, Rode B, Jusic D, Soos E (1981) Application of human leucocyte interferon in patients with urinary bladder papillomatosis, breast cancer and melanoma. Lancet 1: 1022–1024PubMedGoogle Scholar
  24. 24.
    Ikic D, Krusic J, Kirhmajer V, Knezevic M, Maricic Z, Rode B, Jusic D, Soos E (1981) Application of human leucocyte interferon in patients with carcinoma of the uterine cervix. Lancet 1: 1027–1030PubMedCrossRefGoogle Scholar
  25. 25.
    Ikic D, Padovan I, Brodarec I, Knezevic M, Soos E (1981) Application of human leucocyte interferon in patients with tumours of the head and neck. Lancet 1: 1025–1027PubMedGoogle Scholar
  26. 26.
    Ikic D, Singer Z, Beck M, Soos E, Sips DJ, Jusic D (1981) Interferon treatment of uterine cervical precancerosis. J Cancer Res Clin Oncol 101: 303–308PubMedCrossRefGoogle Scholar
  27. 27.
    Ishihara K (1983) Clinical studies of human fibroblast interferon in malignant tumors of the skin - with special reference to local administration. J Jap Soc Cancer Ther 18: 41–53Google Scholar
  28. 28.
    Ishihara K, Hayasaka K, Yamamoto A, Hasegawa F (1983) Clinical responses of patients with malignant skin neoplasia to intralesional treatment with three types of interferons (a and p). In: Kishida T ( Hrsg) Interferons. Kyoto, pp 222–227Google Scholar
  29. 29.
    Kamidono S, Hamami G, Tomioka O, Fujii A, Ishigami J, Kishida T, Matsuo A (1981) Interferon therapy in urothelial tumor. Kobe J Med Sci 27: 207–212PubMedGoogle Scholar
  30. 30.
    Kato Y, Hattori N, Furue H, Takeuchi S, Nijima T, Kukita A, Takakura K (1983) Antitumor effect of human fibroblast interferon in various malignant tumors. In: Kishida T (Hrsg) Interferons, Kyoto, pp 180–188Google Scholar
  31. 31.
    Koyama Y (1983) Pharmacokinetics and clinical trials of HuIFN-p in malignant tumors. In: Kishida T (Hrsg) Interferons, Kyoto, pp 189–195Google Scholar
  32. 32.
    Krusic J, Kirhmajer V, Knezevic M, Ikic D, Maricic Z, Rode B, Jusic D, Soos E (1981) Influence of human leukocyte interferon on squamous cell carcinoma of uterine cervix: clinical, histological, and histochemical observations. III. Communication. J Cancer Res Clin Oncol 101: 309–315Google Scholar
  33. 33.
    Krusic J, Maricic V, Chylah B (1984) Influence of human leucocyte interferon on squamous cell carcinoma of the uterine cervix: clinical, histological and histochemical observations. Dev Oncol 15: 253–255Google Scholar
  34. 34.
    Linder-Ciccolunghi SN (1985) Improving the acceptability and tolerability of interferon. Therapy in cancer patients. Proc 3rd European Conf Clin Oncol Cancer Nursing, p 8Google Scholar
  35. 35.
    Matsui MS, Solowey WE, Edwalds GD, Cuarini L, Pestka S, Ferrone S, Fisher PB (1986) Potentiation of growth suppression and induction of differentiation in human melanoma cells by the combination of fibroblast and immune interferon. J Invest Der 87: 443Google Scholar
  36. 36.
    Mishina T, Watanabe H, Kobayashi T, Maegawa M, Nakao M, Nakagawa S, Kishida T, Imanishi J, Amagai T, Kita M, Kondo M, Matsumura M (1983) Clinical application of human leucocyte interferon on patients with bladder tumors. In: Kishida T (Hrsg) Interferons, Kyoto, pp 239–242Google Scholar
  37. 37.
    Misset JL, Mathe G (1981) Intrathecal interferon in meningeal leukemia. New Engl J Med 310: 1544Google Scholar
  38. 38.
    Moller BR, Johannesen P, Osther K, Ulmsteen U, Hastrup J, Berg K (1983) Treatment of dysplasia of the cervical epithelium with an interferon gel. Obstet Gynecol 62: 625–629PubMedGoogle Scholar
  39. 39.
    Morita T, Ishikawa S, Tanaka S, Kobayashi Y, Ohba S, Tokue A, Yonese Y, Minato N (1984) Treatment of bladder cancer by topical injection of HBLI. J Jpn Clin Urol 38: 875–878Google Scholar
  40. 40.
    Mughal TI, Robinson WA, Thomas MR, Garvin PR, Entringer M (1984) A phase 2 study of the effect of recombinant interferon a2 (Sch 30 500) (IFN a2) in metastatic malignant melanoma ( MMM ). Clin Res 32: 59AGoogle Scholar
  41. 41.
    Murphy GP (1981) Current report on the interferon program at Roswell Park Memorial Institute. J Surg Oncol 17: 99–111PubMedCrossRefGoogle Scholar
  42. 42.
    Nagai M, Arai T (1984) Clinical effect of interferon in malignant brain tumors. Neurosurg Rev 7: 55–64PubMedCrossRefGoogle Scholar
  43. 43.
    Nagai M (1986) Study of local administration and instillation of IFN-p into brain tumors. In: Medical Tribune Japan (Hrsg) Clinical aspects of interferon-p, pp 4–5Google Scholar
  44. 44.
    Oliver RTD, Waxman JH, Kwok H, Fowler CG, Mathewman P, Blandy JP (1986) Alpha lymphoblastoid interferon for non-invasive bladder cancer. Br J Cancer 53: 432Google Scholar
  45. 45.
    Osther K, Salford LG, Hornmark-Stenstam B, Flodgren P, Christophersen IS, Magnusson K and the Southern Sweden Neuro-Oncology group (1981) Local versus systemic human leukocyte interferon treatment. In: De Maeyer E, Galasso G, Schellekens H (Hrsg) The biology of the interferon system. Elsevier/North-Holland, Amsterdam, pp 415–419Google Scholar
  46. 46.
    Quesada JR, Rios A, Swanson D, Trown P, Gutterman JU (1985) Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J Clin Oncol 3: 1522–1528PubMedGoogle Scholar
  47. 47.
    Rambaldi A, Introna M, Colotta F, Landolfo S, Colombo N, Mangioni C, Mantovani A (1985) Intraperitoneal administration of interferon ß in ovarian cancer patients. Cancer 56: 294–301PubMedCrossRefGoogle Scholar
  48. 48.
    Remy W, Demmler M (1988) Örtliche/intratumorale Interferon-Behandlung von Basaliomen. In: Hofschneider PH (Hrsg) Ergebnisse der Beta-Interferon-Therapie bei chronisch-aktiver Hepatitis B, Multipler Sklerose und Krebserkrankungen. Aktuelle Immunologie 3. W. Zuckschwerdt, München, pp 83–86Google Scholar
  49. 49.
    Rosso R, Nobile MT, Sertoli MR, Giannitelli A, Santi PL, Volpe R, Nicolo G (1985) Antitumoral activity of human fibroblast interferon administered intranodularly. Oncology 42: 86–88PubMedCrossRefGoogle Scholar
  50. 50.
    Salmon SE, Durie BGM, Young L (1983) Effects of cloned human leukocyte interferons in the human tumor stem cell assay. J Clin Oncol 1: 217–225PubMedGoogle Scholar
  51. 51.
    Sato M, Yoshida H, Yanagawa T, Yura Y, Urata M, Hayashi Y (1983) Topical administration of human fibroblast interferon in premalignant lesions arising in oral mucosa. Proc Int Symp InterferonsGoogle Scholar
  52. 52.
    Smith RA, Kingsbury D, Alksne J, James H, Cantell K Distribution of interferon in cerebrospinal fluid after systemic, intrathecal, and intraventricular administration. Proc Am Neurol Ass, 81Google Scholar
  53. 53.
    Schmitz-Dräger BJ, Ebert T, Ackermann R (1986) Intravesical treatment of superficial bladder carcinoma with interferons. World J Urol 3: 218–223CrossRefGoogle Scholar
  54. 54.
    Seto WH, Choo YC, Merigan TC (1984) Local I FN treatment of intraepithelial neoplasia. Antiviral Res 3: 35Google Scholar
  55. 55.
    Slater DE, Krown SE, Pinsky CM (1984) Human leukocyte (a) interferon and Cimetidine in malignant melanoma. Proc Am Soc Clin Oncol 3: 54Google Scholar
  56. 56.
    Spiegel RJ, Spicehandler JR, Jacobs SL, Oden EM (1986) Low incidence of serum neutralizing factors in patients receiving recombinant alfa-2b interferon ( Intron-A ). Am J Med 80: 223–227Google Scholar
  57. 57.
    Torti FM, Lum BL (1987) Superficial bladder cancer. Risk of recurrence and potential role for interferon therapy. Cancer 59: 613–616Google Scholar
  58. 58.
    Turek LA, Byrne JC, Lowy DR, Dvoretzky I, Friedman RM, Howley PM (1982) Interferon induces morphologic reversion with elimination of extrachromosomal viral genomes in bovine papillomavirus-transformed mouse cells. Proc Natl Acad Sci USA 79: 7914–7918PubMedCrossRefGoogle Scholar
  59. 59.
    Ueda S, Hirakawa K, Nakagawa Y, Suzuki K, Kishida T (1983) Brain tumors. In: Sikora K (Hrsg) Interferon and cancer. Plenum, New York, pp 129–140Google Scholar
  60. 60.
    Vilchez CA, Saffe IE, Sortino HE, Molina CA (1986) Use of human I FN and secretory immunoglobulin A in the treatment of cervical dysplasia and carcinoma in situ (CIN) with Koilocitosis. Proc 2nd Cuban Sem Interferon BiotechnologyGoogle Scholar
  61. 61.
    Vose BM, Vanky F, Argov S, Klein E (1977) Natural cytotoxicity in man: activity of lymph node and tumor-infiltrating lymphocytes. Eur J Immunol 7: 753–759CrossRefGoogle Scholar
  62. 62.
    Williams R, Sarosdy M, Catalona W, Chodak G, Vogelzang N, Freiha F, Torti F (1988) Randomized trial of high vs. low dose intravesical interferon alpha 2-B (IFN-A2B) treatment of bladder carcinoma-in-situ (Cis). 21th Congr Int Soc Urol, Buenos AiresGoogle Scholar
  63. 63.
    Wirth M, Schmitz-Dräger BJ, Ackermann R (1985) Functional properties of natural killer cells in carcinoma of the prostate. J Urol 133: 973–978PubMedGoogle Scholar
  64. 64.
    Wussow P von, Block B, Hartmann F, Deicher H (1988) Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer 61: 1071–1074CrossRefGoogle Scholar
  65. 65.
    Zoon KC, Arnheiter H (1984) Studies of the interferon receptor. Pharmac Ther 24: 259–278CrossRefGoogle Scholar
  66. 66.
    Zur Hausen H (1980) Papilloma viruses. In: Tooze J (Hrsg) DNA tumor viruses. Cold Spring Harbour, New York, Cold Spring Harbour Laboratory, pp 371–382Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • B. J. Schmitz-Dräger
  • R. Ackermann

There are no affiliations available

Personalised recommendations